 |
 |
|
Vitrolife exhibits at the 9th International Congress on Lung Transplantation, Paris, France (2010-09-07) |
| Vitrolife will attend the 9th International Congress on Lung Transplantation in Paris, France, 16-17 September. |
 Read more |
|
|
Clinical study shows that the STEEN Solution™ method can increase the number of available lungs for transplantation. (2010-09-07) |
| The results of the HELP (Human ex vivo Lung Perfusion) study on STEEN Solution™ show that transplantation with ex vivo evaluated lungs was at least as good as in the control group. This conclusion was presented during the ISHLT congress in Chicago in April. |
| Read more |
|
|
Several European hospitals choose the STEEN Solution™ method for transplantations (2010-05-03) |
| The Puerta de Hierro hospital in Madrid is the first Spanish hospital to have begun using the STEEN Solution™ method clinically. Lungs from heart-dead donors have been used and the results are very good. |
| Read more |
|
|
Two lung transplantations performed in Manchester using new technology (2010-05-03) |
| The University Hospital of Manchester, England, is now the first clinic outside Sweden to have used the STEEN Solution™ method clinically. Two double lung transplantations have been performed with positive results. “It is exciting to note that Steen Solution™ and lung evaluation outside the body are beginning to become clinical practice in a leading country such as the UK, and that more people with lung disease thereby receive effective treatment,” says Magnus Nilsson, CEO of Vitrolife. |
| Read more |
|
|
Lung transplantations using new technology carried out in North America (2010-05-03) |
| For the first time lung transplantations have been performed in North America using the STEEN Solution™ technology. The transplantations were done in Toronto, Canada, and are part of the study that is being carried out as a basis for the application for sales approval in the USA and Canada. “It is very good to be able to observe that three further patients with lung disease have been able to be helped by means of this new technology, that it has been adopted by North America’s most experienced lung transplantation clinic and that the clinical study involving our unique product is now well underway,” says Magnus Nilsson, Vitrolife’s CEO. |
| Read more |
|
|
|
|
